Outlook Therapeutics Inc

NASDAQ:OTLK   3:59:53 PM EDT
1.53
0.00 (0.00%)
Other Pre-Announcement

Outlook Therapeutics Reports Q2 Loss Per Share $0.09

Published: 05/13/2022 12:12 GMT
Outlook Therapeutics Inc (OTLK) - Outlook Therapeutics Reports Financial Results for Second Quarter Fiscal Year 2022 and Provides Corporate Update.
Q2 Loss per Share $0.09.
at March 31, 2022, Outlook Therapeutics Had Cash and Cash Equivalents of $58.4 Million.
Cash and Cash Equivalents on Hand Are Expected to Provide Funding Into First Calendar Quarter of 2023.